Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (foamy virus vector)
- Development stage
- Preclinical
- Lead developer
- Academy of Athens
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-CD19 CAR-T cells (foamy virus vector) is an investigational, allogeneic, 'off-the-shelf' chimeric antigen receptor (CAR) T-cell therapy. Developed by researchers at the Biomedical Research Foundation of the Academy of Athens and the University of Thessaly, this cell therapy is engineered using a foamy virus (FV) vector rather than conventional lentiviral or retroviral vectors. Foamy virus vectors are non-pathogenic retroviruses characterized by a safe integration profile, reduced risk of insertional mutagenesis, and a large transgene packaging capacity. The therapy targets B-lymphocyte antigen CD19, a cell surface protein highly expressed on B-cell malignancies, and has demonstrated potent in vitro cytotoxicity against CD19-positive lymphoma cell lines.
- Other names
- anti-CD19 CAR-T cells (FV vector)foamy virus-derived anti-CD19 CAR-T cellsFV-derived anti-CD19 CAR-T cells
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (foamy virus vector).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (foamy virus vector).